Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cynata Therapeutics Limited ( (AU:CYP) ) just unveiled an announcement.
Cynata Therapeutics Limited announced a change in the director’s interest, specifically regarding Dr. Paul K Wotton’s securities. The change involves the expiry of 300,000 unlisted options exercisable at $0.97, resulting in Dr. Wotton now holding 220,000 unlisted options and 585,076 ordinary shares. This update reflects the company’s ongoing management of its securities and may influence stakeholder perceptions regarding director engagement and investment strategies.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited operates in the biotechnology industry, focusing on the development of stem cell therapies. The company is engaged in creating innovative treatments through its proprietary Cymerus™ technology, targeting a range of diseases and conditions.
YTD Price Performance: 18.75%
Average Trading Volume: 207,705
Technical Sentiment Signal: Buy
Current Market Cap: A$67.67M
For an in-depth examination of CYP stock, go to TipRanks’ Overview page.